Abstract
Vasoactive intestinal peptide (VIP) is a basic 28 amino acid peptide that binds to a member of the class II family of G proteincoupled receptors (GPCRs). It is widely expressed throughout the body and plays an important role in numerous biological functions. VIP acts via three different GPCRs: VPAC1, VPAC2, and PAC1, which have been identified in various tissues, including brain, lung, kidney, gastrointestinal tract, tongue, and also on immunocompetent cells such as macrophages and lymphocytes. There is mounting evidence that VIP expression and signaling is altered in numerous neurological disorders, and it is becoming apparent that VIP and its receptors could be therapeutic loci for the treatment of several pathological conditions of the central nervous system. In this review, we describe the pathology of several major neurological disorders and discuss the potential pharmacotherapeutic role of VIP and its receptors for the treatment of disorders such as Alzheimers disease, Parkinsons disease, and Autism Spectrum Disorders.
Keywords: Alzheimer's disease, Autism Spectrum Disorders, neurological disorders, Parkinson's disease, pharmacotherapeutics, pituitary adenylate cyclase-activating peptide, vasoactive intestinal peptide
CNS & Neurological Disorders - Drug Targets
Title: Therapeutic Potential of Vasoactive Intestinal Peptide and its Receptors in Neurological Disorders
Volume: 9 Issue: 5
Author(s): Caitlin M. White, Sunggoan Ji, Huan Cai, Stuart Maudsley and Bronwen Martin
Affiliation:
Keywords: Alzheimer's disease, Autism Spectrum Disorders, neurological disorders, Parkinson's disease, pharmacotherapeutics, pituitary adenylate cyclase-activating peptide, vasoactive intestinal peptide
Abstract: Vasoactive intestinal peptide (VIP) is a basic 28 amino acid peptide that binds to a member of the class II family of G proteincoupled receptors (GPCRs). It is widely expressed throughout the body and plays an important role in numerous biological functions. VIP acts via three different GPCRs: VPAC1, VPAC2, and PAC1, which have been identified in various tissues, including brain, lung, kidney, gastrointestinal tract, tongue, and also on immunocompetent cells such as macrophages and lymphocytes. There is mounting evidence that VIP expression and signaling is altered in numerous neurological disorders, and it is becoming apparent that VIP and its receptors could be therapeutic loci for the treatment of several pathological conditions of the central nervous system. In this review, we describe the pathology of several major neurological disorders and discuss the potential pharmacotherapeutic role of VIP and its receptors for the treatment of disorders such as Alzheimers disease, Parkinsons disease, and Autism Spectrum Disorders.
Export Options
About this article
Cite this article as:
M. White Caitlin, Ji Sunggoan, Cai Huan, Maudsley Stuart and Martin Bronwen, Therapeutic Potential of Vasoactive Intestinal Peptide and its Receptors in Neurological Disorders, CNS & Neurological Disorders - Drug Targets 2010; 9 (5) . https://dx.doi.org/10.2174/187152710793361595
DOI https://dx.doi.org/10.2174/187152710793361595 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sleep Disturbance is Associated with Incident Dementia and Mortality
Current Alzheimer Research The Role of Aβ Peptides in Alzheimers Disease
Protein & Peptide Letters Creatine and the Liver: Metabolism and Possible Interactions
Mini-Reviews in Medicinal Chemistry Advances in Neuroimaging for HIV-1 Associated Neurological Dysfunction: Clues to the Diagnosis, Pathogenesis and Therapeutic Monitoring
Current HIV Research Emerging Risk Factors for Dementia: The Role of Blood Pressure Variability
CNS & Neurological Disorders - Drug Targets Functional Magnetic Resonance Imaging in Abstinent MDMA Users: A Review
Current Drug Abuse Reviews Phytochemical Therapies in Vascular Functioning: A Molecular Approach
Current Vascular Pharmacology Chemical Composition and Biological Effects of Essential Oils from Some Aromatic and Medicinal Plants
The Natural Products Journal Hydrophobic Plant Antioxidants. Preparation of Nanoparticles and their Application for Prevention of Neurodegenerative Diseases. Review and Experimental Data
Current Topics in Medicinal Chemistry Colostral Proline-Rich Polypeptides - Immunoregulatory Properties and Prospects of Therapeutic Use in Alzheimers Disease
Current Alzheimer Research Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Commonalities in Biological Pathways, Genetics, and Cellular Mechanism between Alzheimer Disease and Other Neurodegenerative Diseases: An In Silico-Updated Overview
Current Alzheimer Research Highly Active Antiretroviral Therapy and Cardiovascular Complications in HIV-Infected Patients
Current Pharmaceutical Design Editorial (Hot Topic: Fragile X Families: A Lifespan Perspective)
Current Psychiatry Reviews Is Alpha-Synuclein Pathology a Target for Treatment of Neurodegenerative Disorders?
Current Alzheimer Research Mineralocorticoid Receptor Blockade in the Protection of Target Organ Damage
Cardiovascular & Hematological Agents in Medicinal Chemistry Multifunctional Ligands Targeting Phosphodiesterase as the Future Strategy for the Symptomatic and Disease-Modifying Treatment of Alzheimer’s Disease
Current Medicinal Chemistry Is Educational Attainment Associated with Increased Risk of Mortality in People with Dementia? A Population-based Study
Current Alzheimer Research Biomarkers in Amyotrophic Lateral Sclerosis: Is There A Neurovascular Pathway?
Current Neurovascular Research Bioactivity of Chitosan and Its Derivatives
Current Organic Chemistry